Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded

Türkan Acar; Mehmet Fevzi Öztekin; Neşe Öztekin

doi:10.21601/ortadogutipdergisi.365144

ORTADOĞU TIP DERGİSİ - ORTADOGU MEDICAL JOURNAL

Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded

Karbamazepin monoterapisine yanıt alınamayan parsiyel epilepsi hastalarında levetiracetam veya zonisamid ek tedavilerinin karşılaştırılması

Türkan Acar ¹ ^* , Mehmet Fevzi Öztekin ², Neşe Öztekin ³

More Detail

Ortadogu Tıp Derg, Volume 10, Issue 4, pp. 511-515

https://doi.org/10.21601/ortadogutipdergisi.365144

OPEN ACCESS

Download Full Text (PDF)

Abstract

Aim: Partial epilepsy is the most common type of seizure and in some patients sufficient seizure control may not
be achieved despite monotherapy and even polytherapy. Our aim in this study was to compare the efficacy and side
effects of levetiracetam or zonisamide add-on treatments in patients without seizure control with carbamazepine
monotherapy.
Material and Method: Thirty-two patients aged 18-54 years who were followed for at least 1 year by carbamazepine
monotherapy were included in the study. Zonisamide was added to 16 of these patients, and levetiracetam was added
to 16 of these patients. Patients were monitored for 3 months to be held at constant titration after the insertion therapy.
Results: The mean age of the group to which zonisamide was added was 33.4±10.6 (7 males, 9 females) while the
levetiracetam group had 35.7±11.5 (8 males, 8 females). When 3-month follow-up period was evaluated in terms of
total number of seizures, there was no statistically significant difference between the two groups in terms of efficacy
and side effects (p=0,377).
Conclusion: Levetiracetam or zonisamide can be used in patients with partial seizures with similar side effects and
fewer side effects in patients with seizure control.

Keywords: Levetiracetam, zonisamide, partial epilepsy

Öz

Amaç: Parsiyel epilepsi en sık görülen nöbet tipi olup bazı hastalarda monoterapi ve hatta politerapiye rağmen yeterli nöbet kontrolü sağlanamayabilir. Bu çalışmadaki amacımız karbamazepin monoterapisi ile nöbet kontrolü sağlanamamış hastalarda levetirasetam veya zonisamid ekleme tedavilerinin etkinlik ve yan etki bakımından karşılaştırılması hedeflenmiştir.
Gereç ve Yöntem: 18-54 yaş arası, en az 1 yıldır karbamazepin monoterapisi ile takip edilen 32 hasta çalışmaya alındı. Bu hastaların 16’sına zonisamid, 16’sına levetirasetam eklendi. Hastalar ekleme tedavisi sonrası sabit titrasyonda tutulacak şekilde 3 ay boyunca izlendi.
Bulgular: Zonisamid eklenen grubun yaş ortalaması 33,4±10,6 (7 erkek, 9 kadın) iken levetirasetam grubunda 35,7±11,5 (8 erkek, 8 kadın) idi. Toplam nöbet sayıları bakımından 3 aylık izlem süresi değerlendirildiğinde her iki grup arasında etkinlik ve yan etki bakımından istatistiksel olarak anlamlı fark saptanmamıştır (p=0,377).
Sonuç: Parsiyel nöbetlerin ekleme tedavilerinde levetirasetam veya zonisamid benzer oranda etkin olup nöbet kontrolü sağlanamayan hastalarda yan etki profilinin de az olması nedeniyle kullanılabilir.

Keywords: Levetirasetam, zonisamid, parsiyel epilepsi

References

Blume WT, Luders HO, Mizrahi E, Tassinari C, van Emde BW, Engel Jr. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001;42:1212-8.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-68.
Lavados J, Germain I, Morales A, Campero M, Lavados P. A descriptive study of epilepsy in the district of EL Salvador, Chile, 1984-1988. Acta Neurol Scand 1992;91:718-29.
Joensen P. Prevalence, incidence and classification of epilepsy in Faroes. Acta Neurol Scand 1986;74:150-5.
Steinlein OK. Genes and mutations in idiopathic epilepsy. Am J Med Genet 2001;106:136-45.
French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of new antiepileptic drugs, I: Treatment of new onset epilepsy: Report of TTA and OSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004;45:401-9.
Bora İ, Yeni SN, Gürses C. Epilepsi. Nobel Tıp Kitapevleri 2008.
Baulac M, Leppik I.E. Efficacy and safety od adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75:75-83.
Seino M, Fıjitani B. Zonisamide, clinical efficacy and use in epilepsy. In: Levy R.H (Ed), Antiepileptic drugs. Lippincott, Williams, Wilkins, Philadelphia 2002;5:885-91.
Thomas G, McCabe P.. Clinical use of zonisamide in generalized seizure disorders. Epilepsia 2005;46:2294.
Conry JA, Ramsey RE, Vossler D, Glauser TA. Efficacy and safety of zonisamide as adjunctive therapy for primary generalized epilepsy. Epilepsia 2005;46:2350.
O’Rourke D, Flynn C, White M, Doherty C, Delanty N. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy. Epilepsia 2005;46:301.
Welty T.E, Kuzniecky R, Faught E. Outcome of using new AED in juvenile myoclonic epilepsy. Neurology 2003;60:147.
Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK. Randomized controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-7.
Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam, 3000 mg/d in patients with refractory partial seizures:a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-83.
Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2005;4:1416.
Faught E, Ayala R, Montouris G, Leppik I. Randomize controlled trial of zonisamide for the treatment of refractory partial onset seizures. Neurology 2001;57:1774-9.
Harden C. Safety profile of levetiracetam. Epilepsia 2001;42:36-9.

Citation

Acar T, Öztekin MF, Öztekin N. Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded. Ortadogu Tıp Derg. 2018;10(4):511-5. https://doi.org/10.21601/ortadogutipdergisi.365144

Acar, T., Öztekin, M. F., & Öztekin, N. (2018). Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded. Ortadoğu Tıp Dergisi, 10(4), 511-515. https://doi.org/10.21601/ortadogutipdergisi.365144

Acar, T., Öztekin, M. F., and Öztekin, N. (2018). Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded. Ortadoğu Tıp Dergisi, 10(4), pp. 511-515. https://doi.org/10.21601/ortadogutipdergisi.365144

Acar T, Öztekin MF, Öztekin N. Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded. Ortadogu Tıp Derg. 2018;10(4), 511-515. https://doi.org/10.21601/ortadogutipdergisi.365144

Acar, Türkan, Mehmet Fevzi Öztekin, and Neşe Öztekin. "Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded". Ortadoğu Tıp Dergisi 2018 10 no. 4 (2018): 511-515. https://doi.org/10.21601/ortadogutipdergisi.365144

Acar, Türkan et al. "Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded". Ortadoğu Tıp Dergisi, vol. 10, no. 4, 2018, pp. 511-515. https://doi.org/10.21601/ortadogutipdergisi.365144